ReviewDrugs2014
T-cell trafficking and anti-adhesion strategies in inflammatory bowel disease: current and future prospects.
Review in Drugs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 38 citations in OpenAlex.
- Identification of Differentially Expressed Genes and miRNAs for Ulcerative Colitis Using Bioinformatics Analysis.Frontiers in genetics · 2022Article
- Dysbiosis of gut microbiota in inflammatory bowel disease: Current therapies and potential for microbiota-modulating therapeutic approaches.Bosnian journal of basic medical sciences · 2021Review
- Protective Effects of ALDH1A Enzyme Inhibition onNutrients · 2020Article
- Discovery of a Novel Multi-Strains Probiotic Formulation with Improved Efficacy toward Intestinal Inflammation.Nutrients · 2020Article
- GPBAR1 Activation by C6-Substituted Hyodeoxycholane Analogues Protect against Colitis.ACS medicinal chemistry letters · 2020Article
- Managing Patients with Inflammatory Bowel Disease Who Develop Prostate Cancer.Digestive diseases and sciences · 2020Review
- Oligonucleotides-A Novel Promising Therapeutic Option for IBD.Frontiers in pharmacology · 2019Review
- On cell death in the intestinal epithelium and its impact on gut homeostasis.Current opinion in gastroenterology · 2018Review
- Chemokines and Chemokine Receptors as Therapeutic Targets in Inflammatory Bowel Disease; Pitfalls and Promise.Journal of Crohn's & colitis · 2018Review
- Inflammatory Bowel Disease: Updates on Molecular Targets for Biologics.Gut and liver · 2017Review
- Article
- The many ways tissue phagocytes respond to dying cells.Immunological reviews · 2017Review
- Metabolic Variability of a Multispecies Probiotic Preparation Impacts on the Anti-inflammatory Activity.Frontiers in pharmacology · 2017Article
- Alicaforsen, an antisense inhibitor of ICAM-1, as treatment for chronic refractory pouchitis after proctocolectomy: A case series.United European gastroenterology journal · 2016Article
- Vedolizumab for the treatment of moderately to severely active ulcerative colitis.Pharmacotherapy · 2015Review
- GPR15: a tale of two species.Nature immunology · 2015Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
The medical management of idiopathic inflammatory bowel disease (IBD) has historically been based upon the use of broad-spectrum anti-inflammatory drugs such as corticosteroids and thiopurines. Recently, the identification of novel mechanisms central to the pathophysiology of IBD has provided more specific targets, including inhibition of leukocyte trafficking to the gut. In this article, we discuss the molecular biology of intestinal leukocyte trafficking and review the emerging therapies that target this process, including vedolizumab, natalizumab, etrolizumab, PF-547659, alicaforsen, efalizumab, and emerging members of this class.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.